The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing –Remitting and Secondary Progressive Multiple Sclerosis
AbstractMultiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medications that slow disease progression by immunomodulatory action. Fingolimod and siponimod have similar mechanisms of action, and consequently, their therapeutic effects may be comparable. However, while fingolimod is mainly used for relapsing –remitting MS (RRMS), siponimod, according to EMA label, is recommended for active secondary progressive MS (SPMS). Clinicians and scie...
Source: Drugs in R&D - August 28, 2023 Category: Drugs & Pharmacology Source Type: research
A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivation
Rev Neurol (Paris). 2023 Aug 24:S0035-3787(23)01006-8. doi: 10.1016/j.neurol.2023.03.028. Online ahead of print.ABSTRACTThe frequency of switches between Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS) has increased considerably over previous years. Between fingolimod and anti-CD20 therapies, a 1-month washout period is usually recommended. However, disease reactivations are frequent after fingolimod (Fg) cessation. Using a retrospective observational monocentric exposed/non-exposed cohort study, we investigated the efficacy and the safety of a shorter washout period (WP) between Fg and anti-CD20. We compared...
Source: Revue Neurologique - August 26, 2023 Category: Neurology Authors: S Gassama A Garmendia F X Lejeune M Boudot de la Motte C Louapre C Papeix E Maillart T Roux Source Type: research
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020
Conclusions
Fertility rate in women with MS remains below the general population. Family planning and subsequent DMT decisions should aim to achieve successful pregnancy, delivery and breastfeeding outcomes, while controlling disease activity. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 14, 2023 Category: Neurosurgery Authors: Moccia, M., Affinito, G., Fumo, M. G., Giordana, R., Di Gennaro, M., Mercogliano, M., Carotenuto, A., Petracca, M., Lanzillo, R., Triassi, M., Brescia Morra, V., Palladino, R. Tags: Multiple sclerosis Source Type: research
Fingolimod-responsive complex hyperkinetic movement disorder in neuromyelitis optica spectrum disorder
Background:Neuromyelitis optica spectrum disorder (NMOSD) can present with hyperkinetic movement disorders, such as dystonia, myoclonus, and chorea/ballism. Occasionally, the movements are complex, posing a diagnostic and therapeutic challenge. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - August 1, 2023 Category: Neurology Authors: R.E. Cortes, J.A. Vatanagul, G. Saranza Source Type: research
Fingolimod In HPS: Assess and Then Judge, a Potential Ray of Hope
None. (Source: Journal of Hepatology)
Source: Journal of Hepatology - July 27, 2023 Category: Gastroenterology Authors: Sukriti Baweja, Chhagan Bihari, Anupama Kumari, Dinesh Mani Tripathi, Shiv Kumar Sarin Tags: Letter to the Editor Source Type: research
Reply to: Correspondence on “Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod”
We appreciate Dr Raevens and Dr Ashraf et al., for their interest in our study, which investigated the role of sphingosine-1-phosphate (S1P) in patients with hepatopulmonary syndrome (HPS), and of the S1P agonist fingolimod as a therapeutic option in an experimental model of HPS.1 (Source: Journal of Hepatology)
Source: Journal of Hepatology - July 27, 2023 Category: Gastroenterology Authors: Sukriti Baweja, Chhagan Bihari, Anupama Kumari, Dinesh Mani Tripathi, Shiv Kumar Sarin Tags: Letter to the Editor Source Type: research
A Novel Drosophila-based Drug Repurposing Platform Identified Fingolimod As a Potential Therapeutic for TDP-43 Proteinopathy
AbstractPathogenic changes to TAR DNA-binding protein 43 (TDP-43) leading to alteration of its homeostasis are a common feature shared by several progressive neurodegenerative diseases for which there is no effective therapy. Here, we developedDrosophila lines expressing either wild type TDP-43 (WT) or that carrying an Amyotrophic Lateral Sclerosis /Frontotemporal Lobar Degeneration-associating G384C mutation that recapitulate several aspects of the TDP-43 pathology. To identify potential therapeutics for TDP-43-related diseases, we implemented a drug repurposing strategy that involved three consecutive steps. Firstly, we ...
Source: Neurotherapeutics - July 26, 2023 Category: Neurology Source Type: research
Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University
This study aims to investigate and compare adherence, adverse event (AE) profiles, and frequencies, main reasons for treatment discontinuation under Teriflunomide (TERI), Dimethyl Fumarate (DMF), and Fingolimod (FNG) for relapsing-remitting MS (RRMS) patients. This study is designed to explore patient-reported experiences in real-life settings.METHODS: Patients who were older than 18 years with a definite diagnosis of RRMS and no history of stem-cell transplantation were included. Outpatient clinic data files at the Neurology Department of Marmara University from June 2012 to June 2019 were examined retrospectively.RESULTS...
Source: Turkish Journal of Medical Sciences - July 21, 2023 Category: General Medicine Authors: Ezgi Vural Esin Engin G ülin Sünter Kadriye A ğan Yıldırım Dilek G ünal Source Type: research
